A New Drug to Target Cancer Cell Enzymes
In patients with metastatic pancreatic cancer, researchers are comparing FOLFIRINOX, the standard treatment, with FOLFIRINOX plus CPI-613, a new drug…
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
Combining Immunotherapy and Targeted Therapy for Pancreatic Cancer
Researchers are combining immunotherapy and targeted therapy in a clinical trial for pancreatic cancer patients on platinum-based chemotherapy.
Living Longer with Pancreatic Neuroendocrine Tumors
Dr. Pamela Hodul explains some of the different types of pancreatic neuroendocrine tumor (PNET) and how rare they are, and some treatment options.
Testing a New Drug on Advanced Pancreatic Neuroendocrine Tumors
In a clinical trial, the new drug sapanisertib is being tested for its effectiveness against pancreatic neuroendocrine tumors (PNETs).
Adding a New Drug to Standard Treatment for Metastatic Pancreatic Cancer
A clinical trial tests the effectiveness of napabucasin, a drug that affects the signaling pathways of cancer stem cells.
Testing the Effect of a Malaria Drug on Standard Treatment
A clinical trial tests whether a malaria drug can make standard chemotherapy for advanced pancreatic cancer more effective.
